Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...
Caliway Biopharmaceuticals (Caliway) announced that the European Medicines Agency (EMA) granted Orphan Drug Designation (ODD) to its novel small molecule drug, CBL-514, for the treatment of Dercum's ...
Immuneering Corp. Class A ( (IMRX) ) has released its Q3 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented ...
The US Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases ...
“We are pleased to have been granted orphan drug designation by the U.S. FDA for AT-02 in ATTR amyloidosis,” said Gregory Bell, M.D., Chief Medical Officer at Attralus. “Current approved therapies for ...
The Food and Drug Administration (FDA) has granted Orphan Drug designation to AT-02 for the treatment of transthyretin-associated amyloidosis (ATTR). AT-02 is a fusion protein of humanized ...
Caliway’s drug molecule CBL-514 to treat Dercum’s disease receives EMA orphan drug designation: New Taipei City Thursday, November 14, 2024, 16:00 Hrs [IST] Caliway Biopharmac ...
The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis ...